期刊文献+

Long-term efficacy,safety and biocompatibility of a novel sirolimus eluting iron bioresorbable scaffold in a porcine model

原文传递
导出
摘要 Iron is considered as an attractive alternative material for bioresorbable scaffolds(BRS).The sirolimus eluting iron bioresorbable scaffold(IBS),developed by Biotyx Medical(Shenzhen,China),is the only iron-based BRS with an ultrathin-wall design.The study aims to investigate the long-term efficacy,safety,biocompatibility,and lumen changes during the biodegradation process of the IBS in a porcine model.A total of 90 IBSs and 70 cobaltchromium everolimus eluting stents(EES)were randomly implanted into nonatherosclerotic coronary artery of healthy mini swine.The multimodality assessments including coronary angiography,optical coherence tomography,micro-computed tomography,magnetic resonance imaging,real-time polymerase chain reaction(PCR),and histopathological evaluations,were performed at different time points.There was no statistical difference in area stenosis between IBS group and EES group at 6 months,1year,2 years and 5 years.Although the scaffolded vessels narrowed at 9 months,expansive remodeling with increased mean lumen area was found at 3 and 5 years.The IBS struts remained intact at 6 months,and the corrosion was detectable at 9 months.At 5 years,the iron struts were completely degraded and absorbed in situ,without in-scaffold restenosis or thrombosis,lumen collapse,aneurysm formation,and chronic inflammation.No local or systemic toxicity and abnormal histopathologic manifestation were found in all experiments.Results from real-time PCR indicated that no sign of iron overload was reported in scaffolded segments.Therefore,the IBS shows comparable efficacy,safety,and biocompatibility with EES,and late lumen enlargement is considered as a unique feature in the IBS-implanted vessels.
出处 《Bioactive Materials》 SCIE CSCD 2024年第9期135-146,共12页 生物活性材料(英文)
基金 supported by National Key R&D Program of China(grant number 2018YFC1106600) Shenzhen Industrial and Information Technology Bureau(20180309174916657) Science,Technology and Innovation Commission of Shenzhen Municipality(grant number GJHZ20180418190517302) Natural Science Foundation of China(grant number 52101282).
  • 相关文献

参考文献6

二级参考文献206

  • 1Linyuan Han,Zhenwei Zhang,Jianwei Dai,Xuan Li,Jing Bai,Zhihai Huang,Chao Guo,Feng Xue,Chenglin Chu.In vitro bio-corrosion behaviors of biodegradable AZ31B magnesium alloy under static stresses of different forms and magnitudes[J].Journal of Magnesium and Alloys,2023,11(3):1043-1056. 被引量:3
  • 2Moses JW, Leon MB, Popma J J, Fitzgerald P J, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323. 被引量:1
  • 3Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. 被引量:1
  • 4Erne P, Schier M, Resink TJ. The road to Ioloabsorbal01e stents: reaching clinical reality? Cardiovasc Intervent Radiol 2006; 29: 11-16. 被引量:1
  • 5Wentzel J J, Whelan DM, van der Giessan WJ, van Beusekom HM, Andhyiswara I, Serruys PW, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000; 33: 1287-1295. 被引量:1
  • 6Gy6ngy6si M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000; 35: 1580-1589. 被引量:1
  • 7Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910. 被引量:1
  • 8ColomboA, Karvouni E. Biodegradable stents: "fulfilling the mission and stepping away". Circulation 2000; 102: 371-373. 被引量:1
  • 9Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronarystent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907. 被引量:1
  • 10Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007; 69:128-131. 被引量:1

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部